VOQUEZNA (vonoprazan) tablets

Search documents
Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing
Globenewswire· 2025-08-20 12:00
Core Insights - Phathom Pharmaceuticals, Inc. clarified that a Schedule 13D filing by Frazier Life Sciences will include administrative changes to its reporting approach without indicating a reduction in ownership position by any Frazier fund or individual in Phathom [1] - The differences in the breakout of holdings between funds and individuals are attributed solely to clarifying changes in Frazier's reporting approach, not due to any sale of shares [2] Company Overview - Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases [3] - The company has in-licensed exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), which is marketed in the U.S. under the brand VOQUEZNA® for various gastrointestinal conditions [3]
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
Globenewswire· 2025-07-28 12:00
Core Viewpoint - Phathom Pharmaceuticals, Inc. will host a live webcast on August 7, 2025, to report its second quarter 2025 financial results and provide a business update [1]. Company Overview - Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases [3]. - The company has in-licensed exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) [3]. - Vonoprazan is marketed in the U.S. as VOQUEZNA for various gastrointestinal conditions, including heartburn relief associated with Non-Erosive GERD and treatment of H. pylori infection [3].